Skip to main content
. 2022 Feb 7;126(8):1186–1195. doi: 10.1038/s41416-022-01716-7

Fig. 1. RaDaRTM workflow.

Fig. 1

Tumour tissue from surgical resection was macrodissected and used for whole-exome sequencing to identify somatic mutations. A personalised ctDNA assay was developed for each patient. Tumour and buffy coat DNA were analysed using personalised assays to confirm somatic mutations and exclude clonal haematopoiesis of indeterminate potential (CHIP). Plasma samples were analysed using RaDaRTM panels and high-depth sequencing and ctDNA detection reported per patient.